Antibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF2550 - Provider product page
- Provider
- R&D Systems
- Product name
- Human Osteoactivin/GPNMB Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human Osteoactivin in ELISAs and Western blots. In sandwich immunoassays, less than 2% cross-reactivity with recombinant mouse Osteoactivin is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
NP_002501
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.
GPNMB methylation: a new marker of potentially carcinogenic colon lesions.
Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.
Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.
Exploratory study on the effect of osteoactivin on muscle regeneration in a rat volumetric muscle loss model.
GPNMB ameliorates mutant TDP-43-induced motor neuron cell death.
Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease.
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.
Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species.
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM
Molecular cancer research : MCR 2019 Aug;17(8):1613-1626
Molecular cancer research : MCR 2019 Aug;17(8):1613-1626
Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.
Tajima JY, Futamura M, Gaowa S, Mori R, Tanahashi T, Tanaka Y, Matsuhashi N, Takahashi T, Yamaguchi K, Miyazaki T, Yoshida K
Journal of Cancer 2018;9(2):358-366
Journal of Cancer 2018;9(2):358-366
GPNMB methylation: a new marker of potentially carcinogenic colon lesions.
Ashktorab H, Rahi H, Nouraie M, Shokrani B, Lee E, Haydari T, Laiyemo AO, Siegel P, Brim H
BMC cancer 2018 Nov 6;18(1):1068
BMC cancer 2018 Nov 6;18(1):1068
Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.
Chen C, Okita Y, Watanabe Y, Abe F, Fikry MA, Ichikawa Y, Suzuki H, Shibuya A, Kato M
Cancer research 2018 Nov 15;78(22):6424-6435
Cancer research 2018 Nov 15;78(22):6424-6435
Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.
Ye X, Luke BT, Wei BR, Kaczmarczyk JA, Loncarek J, Dwyer JE, Johann DJ, Saul RG, Nissley DV, McCormick F, Whiteley GR, Blonder J
Oncotarget 2018 May 29;9(41):26431-26452
Oncotarget 2018 May 29;9(41):26431-26452
Exploratory study on the effect of osteoactivin on muscle regeneration in a rat volumetric muscle loss model.
Ma J, Baker AR, Calabro A, Derwin KA
PloS one 2017;12(4):e0175853
PloS one 2017;12(4):e0175853
GPNMB ameliorates mutant TDP-43-induced motor neuron cell death.
Nagahara Y, Shimazawa M, Ohuchi K, Ito J, Takahashi H, Tsuruma K, Kakita A, Hara H
Journal of neuroscience research 2017 Aug;95(8):1647-1665
Journal of neuroscience research 2017 Aug;95(8):1647-1665
Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease.
Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiffmann R, Futerman AH
PloS one 2015;10(3):e0120194
PloS one 2015;10(3):e0120194
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.
Fiorentini C, Bodei S, Bedussi F, Fragni M, Bonini SA, Simeone C, Zani D, Berruti A, Missale C, Memo M, Spano P, Sigala S
Experimental cell research 2014 Apr 15;323(1):100-11
Experimental cell research 2014 Apr 15;323(1):100-11
Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species.
Patel-Chamberlin M, Wang Y, Satirapoj B, Phillips LM, Nast CC, Dai T, Watkins RA, Wu X, Natarajan R, Leng A, Ulanday K, Hirschberg RR, Lapage J, Nam EJ, Haq T, Adler SG
Kidney international 2011 May;79(10):1138-48
Kidney international 2011 May;79(10):1138-48
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM
PloS one 2010 Dec 29;5(12):e15793
PloS one 2010 Dec 29;5(12):e15793
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 1;16(7):2147-56
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 1;16(7):2147-56
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Human Osteoactivin/GPNMB by Western Blot. Western blot shows lysates of U-118-MG human glioblastoma/astrocytoma cell line and T98G human glioblastoma cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human Osteoactivin/GPNMB Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2550) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). Specific bands were detected for Osteoactivin/GPNMB at approximately 95 and 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Osteoactivin/GPNMB in Human Liver. Osteoactivin/GPNMB was detected in immersion fixed paraffin-embedded sections of human liver using Goat Anti-Human Osteoactivin/GPNMB Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2550) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to Kupffer cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.